SynthesisBMC pulmonary medicine2019
Efficacy of glucocorticoids for the treatment of macrolide refractory mycoplasma pneumonia in children: meta-analysis of randomized controlled trials.
Synthesis in BMC pulmonary medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- The efficacy and safety of minocycline as adjuvant therapy in refractory mycoplasma pneumonia in Chinese children: a meta-analysis.Italian journal of pediatrics · 2022Pooled it
- Analysis of the Nursing Effect of Respiratory Critical Illness Based on Refined Nursing Management.Computational and mathematical methods in medicine · 2022Trial
- Current Practice in the Diagnosis and Management ofJournal of Korean medical science · 2026Article
- Efficacy of High-Dose Versus Conventional-Dose Methylprednisolone in Reducing the Risk of Chronic Lung Disease in Chinese Children With Severe Mycoplasma pneumoniae Pneumonia: A Retrospective Study.Pediatric pulmonology · 2026Article
- East Asia as a sentinel: risk-stratified corticosteroid therapy for paediatric macrolide-resistantEuropean respiratory review : an official journal of the European Respiratory Society · 2026Review
- Taming the Inflammation: The Role of Corticosteroids in Pediatric Mycoplasma Pneumonia.Children (Basel, Switzerland) · 2026Review
- Association Between Pre-Admission 48-Hour Fever Burden and Outcomes in Pediatric Mycoplasma Pneumoniae Infection.Mediterranean journal of hematology and infectious diseases · 2026Article
- Effect of intravenous immunoglobulin combined with azithromycin sequential therapy on clinical outcomes and immune response in children withFrontiers in medicine · 2026Article
- The Role of NLR and Ferritin Levels as Biomarkers for Corticosteroid Dosage in Children with RefractoryJournal of inflammation research · 2026Article
- Assessing the Heterogeneous Treatment Effects of Glucocorticoids in Infants and Toddlers with Severe Pneumonia.Biomedicines · 2025Article
- Low-dose versus high-dose methylprednisolone for children with severePediatric investigation · 2025Article
- Fulminant Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in a Young Adult: A Case Report.Cureus · 2025Article
- Epidemiological and clinical characteristics of hospitalized pediatric patients with Mycoplasma pneumoniae pneumonia before and after the COVID-19 pandemic in China: a retrospective multicenter study.BMC infectious diseases · 2025Article
- Lung consolidation absorption time in 238 pediatric cases of mycoplasma pneumoniae pneumonia.Frontiers in pediatrics · 2025Article
- Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.World journal of pediatrics : WJP · 2024Review
- Model based on the automated AI-driven CT quantification is effective for the diagnosis of refractory Mycoplasma pneumoniae pneumonia.Scientific reports · 2024Article
- The role of LDH and ferritin levels as biomarkers for corticosteroid dosage in children with refractory Mycoplasma pneumoniae pneumonia.Respiratory research · 2024Article
- Case report: a co-occurring case of severeFrontiers in medicine · 2024Article
- Heart Failure Associated With Mycoplasma Pneumoniae Infection, A Case and Review of Literature.Journal of community hospital internal medicine perspectives · 2023Article
- Clinical significance of respiratory virus coinfection in children with Mycoplasma pneumoniae pneumonia.BMC pulmonary medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 1 country.
Funding
Abstract
backgroundMycoplasma pneumoniae is one of the most common pathogens causing community acquired pneumonia in children. Although the rate of macrolide-refractory Mycoplasma pneumoniae (MRMP) has increased, systemic glucocorticoids as a treatment option has not been validated yet. The purpose of this study was to assess the efficacy of glucocorticoids add-on in the treatment of MRMP in children through systematic review and meta-analysis.
methodsData sources A systematic literature search was conducted using ten electronic bibliographic databases including English, Korean, Chinese and Japanese languages, up to March 8, 2018. Study selection The study was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist and selected randomized control trials which compared the efficacy of glucocorticoids add-on to macrolide in the treatment of MRMP in children. Data extraction Two independent reviewers extracted: primary outcomes as hospital days, fever duration, and change in C-reactive protein (CRP) and main analysis was performed through meta-analysis with random effects model.
resultsTwenty-four unique randomized controlled trials met the inclusion criteria. The mean length of hospital stay in glucocorticoids treatment group was significantly shorter than that in conventional macrolide-treatment group (Weighted mean difference (WMD) = - 4.03 days). The mean length of fever duration was significantly shorter in the glucocorticoid treatment group in comparison with the conventional treatment group (WMD = -3.32 days). Level of CRP after treatment was significantly lower in the glucocorticoid treatment group than that in the conventional treatment group (WMD = -16.03). Sensitivity analysis and subgroup analysis showed no significant improvement in heterogeneity. As limitations of the study, most of the studies included were from a single country and we were unable to control for heterogeneity across interventions, lack of standardized measures, and different time points of assessments across studies.
conclusionsGlucocorticoid add-on treatment for MRMP can significantly shorten the duration of fever and hospital stay and decrease the level of CRP. These results should be confirmed by adequately powered studies in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.